Revision as of 14:56, 27 January 2021 editFswitzer4 (talk | contribs)Extended confirmed users10,578 editsm Added UNII← Previous edit | Revision as of 04:46, 12 July 2022 edit undoLaundryPizza03 (talk | contribs)Extended confirmed users51,382 edits +Category:Trifluoromethyl compounds; +Category:Fluoroarenes; +Category:Sulfones using HotCatNext edit → | ||
Line 48: | Line 48: | ||
] | ] | ||
] | ] | ||
] | |||
] | |||
] | |||
Revision as of 04:46, 12 July 2022
Pharmaceutical compoundClinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H8F4O4S |
Molar mass | 348.27 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
CX157 (proposed trade name TriRima, formerly Tyrima) is a selective and reversible inhibitor of MAO-A (RIMA). As of 2007 it was in phase II clinical trials for the treatment of depression. In 2013, work on the drug was terminated.
References
- Fielding R, Mielach F, Free J, Pande A (2007). Pharmacokinetics and oral bioavailability of CX157, a reversible selective MAO-A inhibitor, in primates (PDF). 2007 AAPS Annual Meeting & Exposition. Archived from the original (PDF) on 2011-05-26. Retrieved 2009-06-14.
- Clinical trial number NCT00739908} for "A Study of CX157 (TriRima) for the Treatment of Depression (CX157-200)" at ClinicalTrials.gov
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |